Clinical data from the real world: Efficacy analysis of ceritinib (450mg) in ALK-rearrangement non-small-cell lung cancer patients with brain metastases in China
Conclusion: Ceritinib administered at 450 mg QD to ALK-rearrangement NSCLC patients with BM in China exhibited superior ORR and DCR, as well as PFS and event free probability. The estimated 12-month EFP for intracranial lesions improved in patients with prior brain radiotherapy.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Zhixin Qiu Xinhong Xian Chunrong Liu Min Yu Feng Lin Meijuan Huang Ke Wang Source Type: research
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | China Health | Lung Cancer | Lymphoma | Neurology | Non-Small Cell Lung Cancer | Study